Thanks hnbadgr for the repost, I share Veligers sentiment and feel this is just another repeat lawsuit similar to he last one.
As far as the shareprice, we have come too far and provided to much data to the scientific community to be trading at sub 1 billion MC let alone sub $5 a share. This reeks of desperation as we near a MAA submission. He Rett Syndrome trial size was an unfortunate unforseen miss step but that does not negate the deep growing body of evidence that points towards efficacy in multiple diseases.